Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ||
pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete | ||
Sarclisa | Isatuximab | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | ||
Bavencio | Avelumab | Urothelial Carcinoma (UC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Zejula | Niraparib | First Line OC | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete |